TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05850234: A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myel

Sponsor: AstraZeneca · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 232 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$8,246,700

Rescue Site Savings

+$5,458,530

Unlock Full NCT05850234 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05850234 Rescue Dossier →